Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3535

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3535
---
ers and acquisitions, spin-outs, strategic partnerships,
joint ventures, co-marketing, co-promotion, distributorships, development and co-development, restructurings, divestitures, business
combinations and investments on a global basis. Any such transaction(s) may require us to incur non-recurring or other charges, may increase
our near- and long-term expenditures, grow and expand rapidly putting pressure on current resources and capabilities, and may pose significant
integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. Accordingly,
there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction
that we do complete could expose us to liability, delays, and implementation obstacles that could harm our business, financial condition,
operating results, and prospects. We have no current commitment or obligation to enter into any transaction described above other than
ones to which we are already committed.

Risks
Related to Employee Matters

If
we lose key management or scientific personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop
current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market
share and could make us less competitive.

Our
ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain
highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, including our scientific and
medical personnel, including Dr. Elias and Dr. Kurtis. The loss of the services of any of our executive officers, other key employees,
and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development
and harm our business.

To
induce valuable employees to remain at our company, in addition to salary and cash incentives, we intend to provide restricted stock
awards and stock options that vest over time. The value to employees of restricted stock awards and stock options that vest over time
may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract
more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and
development teams may terminate their employment with us on short notice. Our key employees are at-will employees, which means that any
of our employees could leave our employment at any time, with or without notice. In addition